Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 11/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 10/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 5/20 | 0.43 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10261726 | 1.00 | ERAP2 (0.47) | ERAP2LNPEPERAP1SUV39H2LTA4H | |
| SCHEMBL21371612 | 0.99 | ERAP2 (0.46) | ERAP2LNPEPERAP1SUV39H2LTA4H | |
| SCHEMBL19944935 | 0.99 | ERAP2 (0.46) | ERAP2LNPEPERAP1SUV39H2LTA4H | |
| SCHEMBL19486019 | 0.99 | ERAP2 (0.46) | ERAP2LNPEPERAP1SUV39H2LTA4H | |
| SCHEMBL10261730 | 0.91 | ERAP2 (0.47) | ERAP2LNPEPERAP1SUV39H2LTA4H | |
| SCHEMBL12444385 | 0.91 | ERAP2 (0.47) | ERAP2LNPEPERAP1SUV39H2LTA4H | |
| SCHEMBL19445642 | 0.91 | ERAP2 (0.47) | ERAP2LNPEPERAP1SUV39H2LTA4H | |
| SCHEMBL21371981 | 0.90 | ERAP2 (0.46) | ERAP2LNPEPERAP1SUV39H2LTA4H | |
| SCHEMBL19485952 | 0.90 | ERAP2 (0.46) | ERAP2LNPEPERAP1SUV39H2LTA4H | |
| SCHEMBL10262052 | 0.90 | ERAP2 (0.47) | ERAP2LNPEPERAP1SUV39H2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10603294-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10206894-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | ERAP2 646/4885LNPEP 1252/4885ERAP1 1190/4885 |
| US-10603294-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, MMP8 | ERAP2 646/4885LNPEP 1252/4885ERAP1 1190/4885 |
| US-10206894-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, SI | ERAP2 692/4885LNPEP 802/4885ERAP1 1246/4885 |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | ERAP2 646/4885LNPEP 1252/4885ERAP1 1190/4885 |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | MUC1, FUT6, SI | ERAP2 692/4885LNPEP 802/4885ERAP1 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.